Published April 23, 2020 | Version v1
Journal article Open

Advances in Research on the Relationship Between Vitamin D and Coronary Artery Disease in Kawasaki Disease

Authors/Creators

  • 1. Graduate student class 1807, Department of Clinical Medicine, Xi'an Medical University, PR China
  • 2. Children's Hospital, Shaanxi Provincial People's Hospital of Xi'an Jiaotong University, PR China

Description

Abstract

Vitamin D is a fat-soluble vitamin. Many studies have shown that vitaminD not only plays an important role in calcium and phosphorus metabolism, but also participates in immune regulation, substance metabolism, cell proliferation and differentiation. In recent years, the etiology and pathogenesis of (KD) in Kawasaki disease are not clear, but many studies have found that vitaminD deficiency plays an important role in coronary artery disease in patients with KD. Vitamin D participates in KD inflammation and coronary artery damage through nuclear transcription factor-κB (NF-κB) and tumor necrosis factor-expressing transcription factor-α (TNF-α) activity. This review reviews the research progress on the relationship between vitaminD and coronary artery disease in patients with KD.

Notes

International Journal of Clinical and Medical Cases (ISSN:2517-7346)

Files

IJCMC-3-152.pdf

Files (434.9 kB)

Name Size Download all
md5:5ddeab997b07714fbf2e096dd9e50a0e
434.9 kB Preview Download

Additional details

Related works

Is published in
Journal article: https://www.boffinaccess.com/clinical-and-medical-cases/advances-in-research-3-152 (URL)
Journal article: https://www.boffinaccess.com/clinical-and-medical-cases/advances-in-research-3-152/IJCMC-3-152.pdf (URL)

References

  • Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;Apr;135(17):e927-e999.
  • Kim GB, Park S, Eun LY, Han JW, Lee SY, et al. Epidemiology andClinical Features of Kawasaki Disease in South Korea, 2012-2014.[J]. Pediatr Infect Dis J. 2017 May;36(5):482-485.
  • Makino N, Nakamura Y, Yashiro M, Sano T, Ae R, et al.Epidemiological observations of Kawasaki disease in Japan,2013-2014. Pediatr Int. 2018 Jun;60(6):581-587.
  • Manlhiot C, O'Shea S, Bernknopf B, LaBelle M, Chahal N, et al.Epidemiology of Kawasaki Disease in Canada 2004 to 2014:Comparison of Surveillance Using Administrative Data vs Periodic Medical Record Review. Can J Cardiol. 2018 Mar;34(3):303-309.
  • Lin MC, Lai MS, Jan SL. Epidemiologic features of Kawasakidisease in acute stages in Taiwan, 1997-2010: effect of differentcase definitions in claims data analysis. J Chin Med Assoc. 2015Feb;78(2):121-126.
  • Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, et al. Efficacyand limitation of infliximab treatment for children withKawasaki disease intractable to intravenous immunoglobulintherapy: report of an open-label case series. J Rheumatol. 2012Apr;39(4):864-867.
  • Sonoda K, Mori M, Hokosaki T. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr. 2014May;164(5):1128-1132.
  • Levin M, Burgner D. Treatment of Kawasaki disease with antiTNF antibodies. Lancet. 2014 May 17;383(9930):1700-1703.
  • Yim D, Curtis N, Cheung M. An update on Kawasaki disease II:Clinical features, diagnosis, treatment and outcomes. J Paediatr Child Health. 2013 Aug;49(8):614-623.
  • Deng YC, Wang X, Tang XC, Huang CZ, Yang J, et al. Risk factors forcoronary artery lesions secondary to Kawasaki disease in children.Zhongguo Dang Dai Er Ke Za Zhi. 2015 Sep;17(9):927-931.
  • Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul19;357(3):266-281.
  • Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D andbarrier function: A novel role for extra-renal 1 alpha-hydroxylase.Mol Cell Endocrinol. 2004 Feb;215(1-2):31-38.
  • Cozzolino M. Vitamin D: Something new under the sun. Clin Kidney J. 2012 Aug;5(4):285-287.
  • Neme A, Nurminen V, Seuter S, Carlberg C. The vitaminD-dependent transcriptome of human monocytes. J SteroidBiochem Mol Biol. 2016 Nov;164:180-187.
  • Martinesi M, Ambrosini S, Treves C, Zuegel U, Steinmeyer A, etal. Role of vitamin D derivatives in intestinal tissue of patientswith inflammatory bowel diseases. J Crohns Colitis. 2014Sep;8(9):1062-1071.
  • Chung BH, Kim BM, Doh KC, Cho ML, Kim KW, et al. Protectiveeffect of 1α,25-Dihydroxyvitamin D3 on effector CD4+ T cellinduced injury in human renal proximal tubular epithelial cells.PLoS One. 2017 Feb;12(2):e0172536.
  • Chun JK, Jeon BY, Kang DW, Kim DS. Bacille Calmette Guérin(BCG) can induce Kawasaki disease-like features in programmeddeath-1 (PD-1) gene knockout mice. Clin Exp Rheumatol. 2011Jul-Aug;29(4):743-750.
  • Hong JQ, Gao Y, Song J, Zhuo WB, Sun HT. Comparison ofbiological characteristics and immunosuppression betweenhuman amniotic mesenchymal stem cells and bone marrowmesenchymal stem cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi.2016 Jun;24(3):858-864.
  • Bertran T, Brachet P, Vareille-Delarbre M, Falenta J, Dosgilbert A,et al. Slight Pro-Inflammatory Immunomodulation Properties ofDendritic Cells by Gardnerella vaginalis: The "Invisible Man" ofBacterial Vaginosis?. J Immunol Res. 2016;2016:9747480.
  • Suzuki H, Suenaga T, Takeuchi T. Marker of T-cell activationis elevated in refractory Kawasaki disease. Pediatr Int. 2010Oct;52(5):785-789.
  • Qi XL, Chen LL, Sun XG, Li XM, Zhao LH, et al. 1,25-DihydroxyvitaminD3 regulates T lymphocyte proliferation through activation ofP53 and inhibition of ERK1/2 signaling pathway in childrenwith Kawasaki disease. Eur Rev Med Pharmacol Sci. 2017Aug;21(16):3714-3722.
  • Chen YL, Wang JL, Li WQ. Prediction of the risk of coronaryarterial lesions in Kawasaki disease by serum 25-hydroxyvitaminD3. Eur J Pediatr. 2014 Nov;173(11):1467-1471.
  • Wang JL, Wang L, Xing HJ. Changes and significance of serum 25-hydroxy vitamin D3 and T cell subsets in Kawasaki disease. Chinese Journal of Woman and Child Health Research. 2015;(2):355-356.
  • Furukawa S1, Matsubara T, Jujoh K, Yone K, Sugawara T, et al.Peripheral blood monocyte/macrophages and serum tumornecrosis factor in Kawasaki disease. Clin Immunol Immunopathol.1988 Aug;48(2):247-251.
  • Furukawa S1, Matsubara T, Yone K, Hirano Y, Okumura K, etal. Kawasaki disease differs from anaphylactoid purpura andmeasles with regard to tumour necrosis factor-and interleukin 6in serum. Eur J Pediatr. 1992 Jan;151(1):44-47.
  • Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K.Serum levels of p60 soluble tumor necrosis factor receptor duringacute Kawasaki disease. J Pediatr. 1994 May;124(5):721-725.
  • Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, MatsubaraM, et al. NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. ClinicalImmunology.2001 Jun;99:373-377.
  • Matsubara T, Ichiyama T, Furukawa S. Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease Clin Exp Immunol. 2005 Sep;141(3):381-387.
  • Kudo K, Hasegawa S, Suzuki Y, Hirano R, Wakiguchi H, et al.1α,25-DihydroxyvitaminD3 inhibits vascular cellular adhesionmolecule-1 expression and interleukin-8 production in humancoronary arterial endothelial cells. J Steroid Biochem Mol Biol.2012 Nov;132(3-5):290-294.
  • Stio M, Martinesi S, Bruni C, Treves C, Mathieu A, et al. The vitamin D analogue TX 527 blocks NF-κB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J Steroid Biochem Mol Biol. 2007 Jan;103(1):51-60.
  • Bal AK, Prasad D, Pamintuan MA, Mammen-Prasad E, PetrovaA, et al. Timing of intravenous immunoglobulin treatment andrisk of coronary artery abnormalities in children with Kawasakidisease. Pediatr Neonatol. 2014 Oct;55(5):387-392.
  • Jeffery LE, Qureshi OS, Gardner D, Hou TZ, Briggs Z, et al. VitaminD antagonizes the suppressive effect of inflammatory cytokineson CTLA-4 expression and regulatory function. PLoS One. 2015Jul;10(7):e0131539.
  • Pilania RK, Bhattarai D, Singh S. Controversies in diagnosis andmanagement of Kawasaki disease. World J Clin Pediatr. 2018Feb;7(1):27-35.
  • Penna G, Adorini L. 1,25-Dihydroxyvitamin D3 inhibitsdifferentiation, maturation,activation, and survival of dendriticcells leading to impaired alloreactive T cell activation. J Immunol.2000 Mar;164(5):2405-2411.
  • Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, et al.1,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) Tcells to enhance the development of Th2 cells. J Immunol. 2001Nov;167(9):4974-4980.
  • Staeva-Vieira TP, Freedman LP. 1,25-Dihydroxyvitamin D3inhibits IFN-and IL-4 levels during in vitro polarization of primarymurine CD4+ T cells. J Immunol. 2002 Feb;168(3):1181-1189.
  • Cohen-Lahav M, Douvdevani A, Chaimovitz C, Shany S. Theanti-inflammatory activity of 1,25-Dihydroxyvitamin D3 inmacrophages. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):558-562.
  • Martinesi M, Bruni S, Stio M, Treves C. 1,25-Dihydroxyvitamin D3inhibits tumor necrosis factor--induced adhesion molecule expressionin endothelial cells. Cell Biol Int. 2006 Apr;30(4):365-375.
  • Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, et al.Active serum vitamin D levels are inversely correlated withcoronary calcification. Circulation. 1997 Sep;96(6):1755-1760.
  • Stagi S, Rigante D, Lepri G, Matucci Cerinic M, Falcini F, et al.Severe vitamin D deficiency in patients with Kawasaki disease: apotential role in the risk to develop heart vascular abnormalities.Clin Rheumatol. 2016 Jul;35(7):1865-1872.
  • Zhang YD, Dong QW. Significance of changes in endogenous hydrogen sulfide and 25-hydroxyvitamin D3 in children with Kawasaki disease. Journal of imaging research and medical application. 2018;2(15):184-186.
  • Mao Y. Advances in Research on Kawasaki Disease with Coronary Artery Disease. World Latest Medicine Information. 2019;19(19):29-30.
  • Harada K. Intravenous gamma-globulin treatment in Kawasakidisease. Acta Paediatr Jpn, 1991 Dec;33(6):805-810.
  • Carvalho LS, Sposito AC. Vitamin D for the prevention ofcardiovascular disease: are we ready for that?. Atherosclerosis.2015 Aug;241(2):729-740.
  • Andrukhova O, Slavic S, Zeitz U, Riesen SC, Heppelmann MS, et al.Vitamin D is a regulator of endothelial nitric oxide synthase andarterial stiffness in mice. Mol Endocrinol. 2014 Jan;28(1):53-64.
  • Wong MS, Man RY, Vanhoutte PM. Calcium-independentphospholipase a(2) plays a key role in the endotheliumdependent contractions to acetylcholine in the aorta of thespontaneously hypertensive rat. Am J Physiol Heart Circ Physiol.2010 Apr;298(4):H1260-266.
  • Hirata M, Serizawa K, Aizawa K, Yogo K, Tashiro Y, et al.22-Oxacalcitriol prevents progression of endothelial dysfunctionthrough antioxidative effects in rats with type 2 diabetesand early-stage nephropathy. Nephrol Dial Transplant,2013may;28(5):1166-1174.
  • Liu ZY. Analysis of serum 25-hydroxyvitamin D level and its influencing factors in patients with severe pneumonia. Journal of Internal Intensive Medicine. 2018;24(5):78-80.
  • Azrielant S, Shoenfeld Y. Vitamin D and the Immune System. Israel Medical Association Journal. 2017;19(8):510-511.
  • ShenY, Li Y, Bai J. Research progress of vitamin D3 and systemic lupus erythematosus. Chinese Journal of Gerontology. 2016;36(4):1009-1011.
  • Chen XH, Luo XM, Ma XH. Serum 25 hydroxyvitamin D3 in predicting coronary arterial lesions of Kawasaki disease [J]. Chinese Journal of Woman and Child Health Research. 2019;30(5):558-561.
  • Akin F, Ayça B, Köse N, Duran M, Sari M, et al. Serum vitamin Dlevels are independently associated with severity of coronaryartery disease. J Investig Med. 2012 Aug;60(6):869-873.
  • Forman JP, Williams JS, Fisher ND. Plasma 25‑hydroxyvitaminD and regulation of the renin-angiotensin system in humans.Hypertension 2010 May;55(5):1283‑1288.
  • Resnick LM, Müller FB, Laragh JH. Calcium‑regulating hormonesin essential hypertension. Relation to plasma renin activity andsodium metabolism. Ann Intern Med. 1986 Nov;105(5):649‑654.
  • Lin J, Jain S, Sun X, Liu V, Sato YZ, et al. Lipoprotein particleconcentrations in children and adult following Kawasaki disease.J Pediatr. 2014 Oct;165(4):727-731.
  • Baser H, Can U, Baser S, Hidayetoglu BT, Aslan U, et al. Serum totaloxidant/anti-oxidant status, ischemia-modified albumin andoxidized-low density lipoprotein levels in patients with vitaminD deficiency. Arch Endocrinol Metab. 2015 Aug;59(4):318-324.
  • Zheng RL. The correlation between 25- hydroxyl vitaminD3 and serum lipids level in pediatric patients Kawasaki disease [D]. Lanzhou: Lanzhou University.2018:1-38.
  • Xiao R, Chen LQ. Research progress of Kawasaki disease and gene polymorphism. Medical Recapitulate. 2019;25(21):4196-4201.
  • Jiao F, Jindal AK, Pandiarajan V, Khubchandani R, Kamath N, etal. The emergence of Kawasaki disease in India and China. GlobCardiol Sci Pract. 2017 Oct 31;2017(3):e201721.